OpenText, a supplier of a wide range of cybersecurity, AI and other IT management solutions for MSPs, plans to lay off 1,200 employees and add 800 positions as part of a “business optimization ...

Further, Zix will bring approximately 5,600 MSPs to OpenText, and create significant cross-sell opportunities in the OpenText and Zix clouds,” said OpenText CEO Mark Barrenechea. OpenText will ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

OpenText (NASDAQ: OTEX), (TSX: OTEX), has revealed its highly anticipated "Nastiest Malware of 2024" list, spotlighting the year's most notorious cyber threats. Now in its seventh year, OpenText's ...

OpenText stock is one of the few tech stocks that’s been around for decades. But does it have what it takes to recover? One of the company’s key strengths is its long-term contracts with major ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Open Text Corp. (TSX:OTEX) stock is down almost 10% since 2020. Yet, in this same time period, the company has grown its ...

One of the company’s key strengths is its long-term contracts with major global companies. OpenText stock works with a wide range of industries, from healthcare to manufacturing, and partners with ...

Open Text Corp. is an independent software company that provides software products and services that assist organizations in finding, utilizing, and sharing business information from any device.

This page features the latest news about the Actuate Therapeutics stock. Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development Companies will discuss how Lantern's AI ...

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product ...